Literature DB >> 9972675

p53 protein and its messenger ribonucleic acid in human adrenal tumors.

V Adleff1, K Rácz, M Tóth, I Varga, A Bezzegh, E Gláz.   

Abstract

The role of p53 tumor suppressor gene in the pathomechanism of adrenal tumors was investigated by measuring p53 protein and its messenger ribonucleic acid (mRNA) in 12 normal human adrenals as well as in 56 adrenal tumors (7 aldosterone-producing adenomas, 5 adrenocortical adenomas causing Cushing's syndrome, 19 non-hyperfunctioning adrenocortical adenomas, 5 adrenocortical carcinomas, 12 pheochromocytomas, 3 myelolipomas, 4 ganglioneuromas and 1 hemangioma). The p53 protein concentration was significantly increased in aldosterone-producing adenomas (394+/-36 pg/mg cytosolic protein, mean+/-SE, vs 266+/-18 in normal human adrenals), whereas the concentration of this protein in Cushing's adenomas, non-hyperfunctioning adrenocortical adenomas, pheochromocytomas, and in all but one adrenocortical carcinomas was similar to that measured in normal human adrenal tissues. One adrenocortical carcinoma tissue showed very high p53 protein content (3000 pg/mg cytosolic protein). By contrast, myelolipomas (23+/-20) ganglioneuromas (43+/-15) and a hemangioma (11 pg/mg cytosolic protein) had very low p53 protein content. Northern blot analysis revealed the presence of p53 mRNA in each adrenal tissue examined with highest levels in aldosterone-producing and Cushing's adenomas. It is possible that the differences in p53 protein and/or mRNA contents reflect corresponding differences in the pathogenetic importance of p53 alterations in these types of adrenal tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9972675     DOI: 10.1007/BF03348041

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Elevated levels of p53 protein in adrenocortical carcinomas from Costa Rica.

Authors:  A Hildesheim; R Herrero; J Johnson; C Bratti; K Bhatia; I T Magrath; J F Fraumeni
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

Review 4.  Recent advances in the pathogenesis of adrenocortical tumours.

Authors:  C Gicquel; X Bertagna; Y Le Bouc
Journal:  Eur J Endocrinol       Date:  1995-08       Impact factor: 6.664

Review 5.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

6.  Genetic changes in human adrenocortical carcinomas.

Authors:  T Yano; M Linehan; P Anglard; M I Lerman; L N Daniel; C A Stein; C N Robertson; R LaRocca; B Zbar
Journal:  J Natl Cancer Inst       Date:  1989-04-05       Impact factor: 13.506

7.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

8.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

9.  Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique.

Authors:  B Vojtĕsek; C J Fisher; D M Barnes; D P Lane
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

10.  Molecular and immunohistochemical analysis of P53 in phaeochromocytoma.

Authors:  P L Dahia; R C Aguiar; A M Tsanaclis; I Bendit; S P Bydlowski; N M Abelin; S P Toledo
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more
  4 in total

Review 1.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

2.  Assessment of the role of transcript for GATA-4 as a marker of unfavorable outcome in human adrenocortical neoplasms.

Authors:  Angela S Barbosa; Luciano R Giacaglia; Regina M Martin; Berenice B Mendonca; Chin J Lin
Journal:  BMC Endocr Disord       Date:  2004-07-07       Impact factor: 2.763

Review 3.  Adrenal myelolipoma: Controversies in its management.

Authors:  Vasanth G Shenoy; Anuroop Thota; Ravi Shankar; Mallikarjun G Desai
Journal:  Indian J Urol       Date:  2015 Apr-Jun

4.  A rare case of adrenal collision tumor: Myelolipoma and schwannoma in the adrenal gland.

Authors:  Mariangela Gomez; Rohin Mehta
Journal:  SAGE Open Med Case Rep       Date:  2020-05-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.